Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis
Many patients report improved sleep quality and recovery within the first 1-2 weeks
What are the payment terms
TRIUMPH-4 showed 28.7% average body weight loss at 68 weeks on the 12mg dose, as reported by Eli Lilly in December 2025 (peer-reviewed publication pending)
Overall Cohort 1 and 2 combined
Mechanistic studies suggest that the potential direct cardiovascular benefits of SGLT2i include augmentation of signal transducer and activator of transcription 3 (STAT3), inhibition of sodium hydrogen exchange (sodium-hydrogen antiporter 1 [NHE-1]), improved mitochondrial metabolism, modulation of natriuretic peptides, improved vascular stiffness and autonomic tone, reduction of inflammation, and improved cardiac energetics